Insmed Q3 revenue tops $524 million; Brinsupri, Arikayce guidance raised, Japan launch underwayNov 10M&AamikacinbrensocatibUpdated
Roivant and Priovant report positive Phase 3 results for brepocitinib in uveitisOct 21Clinical readoutbrepocitinibRoivant Sciences Ltd.
Roivant details Phase 2 PHocus data for mosliciguat, unveils ongoing Phase 3 PHrontier trialSep 8Clinical readoutRoivant Sciences Ltd.
FDA approves Roivant's LISRAYA for dermatomyositis, launch begins immediatelyAug 28Regulatory decisionbrepocitinibRoivant Sciences Ltd.
Roivant reports Q1 fiscal 2027 results, pipeline on track across four vantsAug 6Quarterly updateRoivant Sciences Ltd.